Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 395-404

  Yoshii, Yukie ^a   Furukawa, Takako ^b   Kiyono, Yasushi ^a   Watanabe, Ryo ^a   Waki, Atsuo ^a   Mori, Tetsuya ^a,c   Yoshii, Hiroshi ^a   Oh, Myungmi ^a   Asai, Tatsuya ^a   Okazawa, Hidehiko ^a   Welch, Michael J ^c   Fujibayashi, Yasuhisa ^a,b  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

64Cu ATSM; Cancer stem cell; CD133; Colon carcinoma; Highly tumorigenic cell

Indexed keywords

CD133 ANTIGEN; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL DENSITY; CELL HYPOXIA; COLON CARCINOMA; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG UPTAKE; ENRICHMENT CULTURE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; STARVATION;

ANIMALS; ANTIGENS, CD; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; COPPER RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOPROTEINS; MALE; MICE; NEOPLASTIC STEM CELLS; ORGANOMETALLIC COMPOUNDS; PEPTIDES; RADIOACTIVE TRACERS; THIOSEMICARBAZONES;

EID: 77952549467     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.12.011     Document Type: Article

References (48)

1. Brown J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999, 59:5863-5870.
2. Padhani A.R., Krohn K.A., Lewis J.S., Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17:861-872.
3. 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
4. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
5. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38:1155-1160.
6. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
7. 4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42:655-661.
8. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000, 14:323-328.
9. Tanaka T., Furukawa T., Fujieda S., Kasamatsu S., Yonekura Y., Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006, 33:743-750.
10. 64Cu using a 12 MeV cyclotron. Nucl Med Biol 2003, 30:535-539.
11. Burgman P., O'Donoghue J.A., Lewis J.S., Welch M.J., Humm J.L., Ling C.C. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005, 32:623-630.
12. 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 2005, 32:21-28.
13. 4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
14. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007, 9:278-283.
15. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51:1641-1648.
16. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
17. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002, 7:249-259.
18. Holland J.P., Giansiracusa J.H., Bell S.G., Wong L.L., Dilworth J.R. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol 2009, 54:2103-2119.
19. 64Cu-ATSM: a comparison study with FDG. Nucl Med Biol 2003, 30:529-534.
20. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261.
21. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890. discussion 95-6.
22. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
23. + cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
24. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67:1-5.
25. Griguer C.E., Oliva C.R., Gobin E., Marcorelles P., Benos D.J., Lancaster J.R., et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008, e3655:3.
26. Tavaluc R.T., Hart L.S., Dicker D.T., El-Deiry W.S. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007, 6:2554-2562.
27. Zhou J., Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 2008, 7:1360-1370.
28. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
29. Ieta K., Tanaka F., Haraguchi N., Kita Y., Sakashita H., Mimori K., et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008, 15:638-648.
30. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
31. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
32. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
33. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
34. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820-824.
35. + cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10:R10.
36. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69:1951-1957.
37. Maeda S., Shinchi H., Kurahara H., Mataki Y., Maemura K., Sato M., et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98:1389-1397.
38. Mehra N., Penning M., Maas J., Beerepoot L.V., van Daal N., van Gils C.H., et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 2006, 12:4859-4866.
39. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
40. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986, 27:235-238.
41. Oh M., Tanaka T., Kobayashi M., Furukawa T., Mori T., Kudo T., et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009, 36:419-426.
42. Fujibayashi Y., Cutler C.S., Anderson C.J., McCarthy D.W., Jones L.A., Sharp T., et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 1999, 26:117-121.
43. Park C.H., Bergsagel D.E., McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971, 46:411-422.
44. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
45. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
46. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
47. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S., Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008, 26:1818-1830.
48. - metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.